Morgan Stanley Downgrades Theravance Biopharma (TBPH) to Underweight, Double Downgrade Following Clinical Business Update
Tweet Send to a Friend
Morgan Stanley analyst Vikram Purohit downgraded Theravance Biopharma (NASDAQ: TBPH) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
